Omalizumab in severe chronic urticaria: are slow and non-responders different?
Conclusions. Patients with severe CSU showing a slow response or not responding at all to omalizumab show impressive similarities. It is currently not possible to predict whether patients with severe CSU and low IgE levels will show a slow response or will not respond to anti-IgE treatment. PMID: 32914943 [PubMed - as supplied by publisher]
CONCLUSION: A 37-year-old man developed infusion-related angioedema with use of infliximab-abda. Discontinuation of the biosimilar product along with supportive care brought about resolution of angioedema. There are no prior published reports of infusion-related angioedema reactions secondary to infliximab-abda use. PMID: 33031494 [PubMed - as supplied by publisher]
Publication date: October 2020Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 8, Issue 9Author(s): Elias Toubi, Ana Maria Giménez-Arnau, Marcus Maurer, Zahava Vadasz
CONCLUSION: In CSU, the prevalence of self-reported drug allergies was higher than the general population. Drug allergy associated with older age, white race and higher BMI while multiple drug allergy also associated with asthma. These CSU sub-populations should be studied to avoid the potential for morbidity associated with less efficacious and more costly drugs. PMID: 33006537 [PubMed - as supplied by publisher]
CONCLUSION: Atopic disorders, previously recognized as predictors of poor sleep, are associated with COPCs after accounting for sleep problems. PMID: 32975542 [PubMed - as supplied by publisher]
Conclusion: Angioedema was the most typical symptom, and propionic acid derivatives were the most frequently reported culprit drugs. The significant risk factors predicting NSAID hypersensitivity were personal history of AR/CRS, onset of NSAID hypersensitivity reaction over 15 years old, and immediate reaction.Int Arch Allergy Immunol
Abstract Anaphylaxis is a life-threatening systemic reaction, normally occurring within one to two hours of exposure to an allergen. The incidence of anaphylaxis in the United States is 2.1 per 1,000 person-years. Most anaphylactic reactions occur outside the hospital setting. Urticaria, difficulty breathing, and mucosal swelling are the most common symptoms of anaphylaxis. The most common triggers are medications, stinging insect venoms, and foods; however, unidentified triggers occur in up to one-fifth of cases. Coexisting asthma, mast cell disorders, older age, underlying cardiovascular disease, peanut and tree...
Discussion There are 8 common foods which compromise 90% of food allergens with those being peanuts, soybeans, cow’s milk, eggs, fish, crustacean/shellfish, wheat and tree nuts. Some people believe that lupin (a legume) is 9th. Legumes belong to the Fabaceae family. They provide protein, fat, vitamins other essential nutrients and therefore are used in the human diet throughout the world. “[A]llergenicity due to consumption of legumes in decreasing order may be peanut, soybean, lentil, chickpea, pea, mung bean and red gram.” Other common legumes include alfalfa, clovers, beans, lupins, mesquite, carob...
Authors: ÇelebİoĞlu E, Akarsu A, Şahİner ÜM Abstract Food allergy (FA) is an increasing problem throughout the world. In the last two decades, the frequency of FA has increased in both children and adults. The prevalence differs according to the research methodology, age and geographic regions, ranging between 2.0 to 10.0%. The most common form of FA is IgE mediated FA. In this form, patients may present with life-threatening condition as anaphylaxis or milder conditions like urticaria, angioedema, sneezing and nausea alone. The gold standard in the diagnosis of FA is oral provocation tests. Epiderm...
Publication date: Available online 8 September 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Phichayut Phinyo, Pattaraporn Koompawichit, Surapon Nochaiwong, Napatra Tovanabutra, Siri Chiewchanvit, Mati Chuamanochan
This article reviews biologic treatments that are currently applied for the treatment of severe chronic urticaria. Monoclonal anti –immunoglobulin E (omalizumab) is effective and safe in many patients, but accessibility and cost constitute barriers to its wider use. Questions on the optimal duration of the treatment and possible symptom recurrences after discontinuing the drug are still raised. A discussion is presented about several other biologics currently under investigation with potential to be incorporated in the near future in patients with severe chronic urticaria.